🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

426 results for “Biotech” Clear

  1. CD19 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    SLE (Systemic Lupus)

    phase 1 mab active

    1 trial

  2. CD19-TriCAR-T/SILK

    Biotech Pharmaceutical Co.,

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  3. CD19-targetd CAR-T

    Chongqing Precision Biotech Co., Ltd

    Juvenile Dermatomyositis

    phase 1 mab active

    1 trial

  4. CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory B-cell Malignancies

    phase 1 mab active

    1 trial

  5. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Ovarian Cancer

    phase 1 mab active

    1 trial

  6. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma

    phase 1 mab active

    1 trial

  7. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Metastatic Tumor

    phase 1 mab active

    4 trials

  8. CD70-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma (RCC)

    phase 1 mab active

    1 trial

  9. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial

  10. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  11. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial

  12. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  13. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial

  14. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer

    phase 1 mab active

    1 trial

  15. Carfilzomib

    ONCOLYTICS BIOTECH INC

    Recurrent Plasma Cell Myeloma

    phase 1 small molecule completed

    1 trial

  16. Chewing Gum

    AXIM BIOTECHNOLOGIES, INC.

    THC

    phase 1 small molecule active

    1 trial

  17. Cyclophosphamide and Fludarabine

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer, Nonsmall Cell, Recurrent

    phase 1 small molecule active

    1 trial

  18. Digoxin

    PUMA BIOTECHNOLOGY, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  19. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  20. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  21. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

  22. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  23. Fecal Microbiota Transplant (FMT)

    MAIA Biotechnology

    Chronic Pouchitis

    phase 1 small molecule active

    1 trial

  24. GCAR1

    Chongqing Precision Biotech Co., Ltd

    Sarcoma

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources